Eli Lilly Study Showed Effient Cost-Effective Versus Clopidogrel 

Eli Lilly & Co. Tuesday said a health economic substudy of the TRITON-TIMI 38 clinical trial showed that treatment with Effient or prasugrel, compared with branded clopidogrel, or Plavix, was more cost effective, and in most cases cost saving, among patients with acute coronary syndromes, or ACS, managed with percutaneous coronary intervention, or PCI, including stenting.
RTTNews